Most pharma companies still rely on the age old batch manufacturing method and today the European Pharma industry faces the major challenge of strong competition from lower cost manufacturers. The trend is disinvestment in Europe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SmartCrys
Advanced intelligence and close loop control for Crystallisa...
2M€
Cerrado
nextBioPharmDSP
Next generation biopharmaceutical downstream process
11M€
Cerrado
INC-FPGS-2010-0656
DESARROLLO DE UN SISTEMA DE GESTIÓN DE LA INFORMACIÓN APLICA...
47K€
Cerrado
CTQ2009-08312
DESARROLLO DE NUEVAS METODOLOGIAS ESPECTRALES PARA EL CONTRO...
134K€
Cerrado
ATRS Instrument
Real time analysis of tablet and capsule dosage during pharm...
71K€
Cerrado
Información proyecto IMPAX
Duración del proyecto: 40 meses
Fecha Inicio: 2016-06-28
Fecha Fin: 2019-10-31
Líder del proyecto
COLVISTEC AG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Most pharma companies still rely on the age old batch manufacturing method and today the European Pharma industry faces the major challenge of strong competition from lower cost manufacturers. The trend is disinvestment in Europe or alternatively investment in innovative manufacturing technologies and more advanced and targeted pharmacological products.
Batch manufacturing implies inflexibility, high costs and poor biological delivery of more advanced new drugs. New techniques like Continuous Manufacturing, extruder based Hot Melt Extrusion and Wet Granulation are the future, allowing for automation, improved efficiency, and proper bioavailability for poorly soluble molecules. Safety and fulfilment of their potential mean these new processes require much more advanced Process Analytical Technology than is currently available.
ColVisTec will extend its unique UV-VIS platform to incorporate NIR and Raman. IMPAX represents the first production monitoring platform to combine three spectra (UV-VIS, NIR and Raman) and will provide extensive, real time, spectroscopy measurements adapted to the extruder environment with pharma software compliant with EMA and FDA regulations.
The initial markets will be Europe and the USA, where ColVisTec is already active. IMPAX users like pharma companies, contract manufacturers and universities will benefit from access to lower cost production and an innovative solution for drug delivery. Important pharma stakeholders (AbbVie, Endcap, FCNW, Catalent, BASF and Reutlingen University) have already shown their interest and support in written form and undertaken to test the new IMPAX platform at their facilities.
IMPAX will contribute to Europe’s pharma industry adopting Industry 4.0 digitalisation and automation principles and will facilitate the European market shift towards CM and PAT techniques boosting the uptake of more competitive manufacturing technologies.